Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
about
Current prospects for the fluoroquinolones as first-line tuberculosis therapyGenomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in SwedenReevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis.A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting.Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assayCorrelation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosisCorrelation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and MoxifloxacinPharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis.Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience.Fluoroquinolones in the treatment of tuberculosis: which is best?gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China.
P2860
Q26823843-BDE384E9-E285-4161-AE1B-6B0229B119DCQ28477040-50C4E4F8-48E8-45F5-AEEA-90BCBCB0EFEFQ30224832-6B3ED8CF-EF37-400F-B311-EA43F5426C88Q34109856-75D71E32-4E64-4BD8-84D3-1A71C7EC3C4EQ34707937-0DEF3C70-988E-4490-B4B8-D852C9122207Q35181330-BE336F6E-660E-4F3E-9194-349378E24EA0Q35960685-C3DD3505-F5A9-4025-897E-0EAB3C613D21Q36086373-603BADBD-4A71-4252-AB99-DEB3AE9B6513Q36794791-9C766D0B-B7DC-44DF-BBB2-C065E38AEC93Q37119998-A50D07AF-B921-405B-B78B-07636724E3C3Q37203747-3F491E46-F722-4054-8D14-CB011C61E7AAQ37426165-23AA48F1-8B34-4837-B31B-DF1CC55577DBQ37434301-BC8FB6FE-CB05-44D1-8C0E-45A18BA06CA0Q37713049-736FB25B-0A68-4676-9C96-037026F5B9E8Q37944716-C6D654DA-9E7A-4987-9DA1-25B961985E0AQ38545953-67B3BD25-A036-433B-898A-D77FAB250DBBQ38845761-334EAD78-9C5E-4452-B428-6A4A06EA87F5Q38929849-E815A508-514C-4306-AFFF-DC29BCA2F3F6Q40922172-8096F34E-673F-49A9-8F95-CCA80D5B2732Q41968982-55623A7C-8FD7-4746-B3E0-10DC9ACE59B7Q42110234-BD91E470-FE7B-4EFD-820C-DD8C2DA26989Q42275450-E360D5C1-D823-447B-8589-AC3A26BFE666Q44398482-D5F5077C-6055-4C98-A1E9-DF4240966501Q46168942-B99EB7FA-8256-468E-91DF-173FEED28675Q50134159-BF5A9A5D-C1E3-4C45-ABEC-83184E1F3745
P2860
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@ast
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@en
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@nl
type
label
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@ast
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@en
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@nl
prefLabel
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@ast
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@en
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@nl
P2093
P356
P1476
Wild-type MIC distributions of ...... etic and pharmacodynamic data.
@en
P2093
A G Johansson
E Chryssanthou
E Sturegård
G Kahlmeter
J Werngren
K A Angeby
M Nordvall
S E Hoffner
P304
P356
10.1093/JAC/DKQ091
P407
P577
2010-03-23T00:00:00Z